Overjet has become one of the most important companies in dental AI because it sits at an unusual intersection: clinical radiograph analysis for providers and AI-assisted review workflows for dental payers. For DSOs, that dual position matters. A platform used by both practices and payers could eventually influence how findings are documented, how claims are reviewed, and how consistency is measured across large dental groups.
The company is best known for FDA-cleared radiograph analysis. Overjet announced FDA clearance for Dental Assist in 2021, followed by Caries Assist in 2022 and additional detection capabilities in 2023. Those clearances give DSO leaders a more concrete basis for evaluation than broad “AI-powered” positioning.
What Is Actually Confirmed
Overjet’s own materials describe the company as serving both providers and payers. In its 2022 Canadian-market announcement, Overjet said its U.S. technology was used by DSOs, independent dentists, and dental insurance carriers representing more than 100 million patients. That is a reach claim, not the same thing as independently verified image volume. For that reason, this article treats scale metrics as company-reported unless a customer, regulator, or audited source publishes them separately.
The more useful DSO question is not the largest number attached to the platform. It is whether Overjet can help a group standardize radiograph review, documentation, patient education, and quality assurance across locations without creating clinical workflow drag.
Why DSOs Are Paying Attention
Large dental groups have a recurring calibration problem. Different providers may describe similar radiographic findings differently, and office-level differences can affect treatment presentation, documentation, and payer interactions. AI does not remove the dentist from the decision. But a well-governed AI layer can give clinicians and operators a more consistent reference point.
That consistency is valuable only if the DSO has a governance model. Leaders need to define when AI annotations are reviewed, how exceptions are handled, how provider feedback is captured, and how patient-facing explanations are approved. Without those controls, AI becomes another visual overlay rather than an operating system for clinical consistency.
The Payer-Provider Angle
Overjet’s payer relationships make it different from provider-only diagnostic AI vendors. If a company supports both clinical review and payer workflows, DSOs should watch whether documentation standards begin to converge around AI-readable findings, attachments, and claim review logic. That could be helpful for cleaner claims, but it also raises practical questions about data sharing, appeal workflows, and how payer-facing AI differs from chairside clinical decision support.
What To Ask Before Standardizing
- Which FDA-cleared indications are live in the product the DSO would actually deploy?
- How does the platform distinguish clinical decision support from diagnosis?
- Can the DSO audit provider adoption, annotation review, and changes in documentation quality by office?
- How are payer-facing workflows separated from provider-facing workflows?
- What customer-reported outcomes can the vendor show for groups similar in size and specialty mix?
Bottom Line
Overjet is a serious enterprise dental AI company, but DSOs should evaluate it with the same discipline they would apply to any clinical infrastructure decision. The strongest case is consistency: better documentation, clearer patient communication, and more structured quality review. The risk is assuming that FDA clearance and large reach numbers automatically translate into operational adoption across every office.
Sources checked: Overjet FDA clearance announcements from 2021, 2022, and 2023; Overjet’s Canadian-market announcement describing provider, payer, and DSO reach; public Overjet product materials. Company scale claims are treated as vendor-reported unless independently confirmed.